European Union Regulatory Draft Guidance on Biogenerics Containing Recombinant Human Erythropoietin
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Locatelli F, Baldamus C, Villa G, Ganea A, Martin de Francisco A
. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002; 40(1):119-25.
DOI: 10.1053/ajkd.2002.33920.
View
2.
Fisher J
. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003; 228(1):1-14.
DOI: 10.1177/153537020322800101.
View
3.
Pavlou A, Reichert J
. Recombinant protein therapeutics--success rates, market trends and values to 2010. Nat Biotechnol. 2004; 22(12):1513-9.
DOI: 10.1038/nbt1204-1513.
View
4.
Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N
. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004; 32(12):1146-55.
DOI: 10.1016/j.exphem.2004.08.004.
View